Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 EV-to-FCF is 13.82 as of Sep. 02, 2026, which is 61% above its 10-year median of 8.61. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 566 Drug Manufacturers companies, Jacobson Pharma ranks better than 65.19% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Jacobson Pharma's Enterprise Value is HK$2,655 Mil.
Jacobson Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was HK$192 Mil. Therefore, Jacobson Pharma's EV-to-FCF for today is 13.82.
The historical rank and industry rank for Jacobson Pharma's EV-to-FCF or its related term are showing as below:
HKSE:02633'
s EV-to-FCF Range Over the Past 10 Years
Min: 3.81 Med: 8.61 Max: 37.84
Current: 13.82
During the past 13 years, the highest EV-to-FCF of Jacobson Pharma was 37.84. The lowest was 3.81. And the median was 8.61.
HKSE:02633's EV-to-FCF is ranked better than 65.19% of 566
companies
in the Drug Manufacturers industry
Industry Median: 19.82
vs HKSE:02633: 13.82
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jacobson Pharma's PE Ratio (TTM) for today is calculated as:
Jacobson Pharma's share price for today is HK$1.035.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.151.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jacobson Pharma EV-to-FCF Related Terms
Jacobson Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's EV-to-FCF falls into.
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was HK$192 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a EV-to-FCF of 13.82 as of Sep. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jacobson Pharma and its competitors. This is 61% above median its historical median of 8.61. Over the past decade, Jacobson Pharma's EV-to-FCF has ranged from 3.81 to 37.84. According to the industry distribution chart, Jacobson Pharma ranks #197 out of 566 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Jacobson Pharma's EV-to-FCF too high?
Jacobson Pharma's current EV-to-FCF of 13.82 is 61% above median its 10-year median of 8.61. Over the past 10 years, this metric has ranged from a low of 3.81 to a high of 37.84. The Drug Manufacturers industry median EV-to-FCF is 19.82. Jacobson Pharma's value of 13.82 is 30.3% below this industry median. Based on the distribution chart, Jacobson Pharma ranks #197 out of 566 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #197 out of 566 companies for EV-to-FCF. This puts Jacobson Pharma in the upper half of its industry. The industry median EV-to-FCF is 19.82. Jacobson Pharma's value of 13.82 is 30.3% below this benchmark. Historically, Jacobson Pharma's own EV-to-FCF has ranged from 3.81 to 37.84 over the past decade. While the company's 10-year median is 8.61 vs. the industry median of 19.82, Jacobson Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.82, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current EV-to-FCF of 13.82 is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current EV-to-FCF is 13.82, which is 61% above median its own 10-year median of 8.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current EV-to-FCF is 13.82, which is 61% above median its 10-year median of 8.61 and 30.3% below the Drug Manufacturers industry median of 19.82. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current EV-to-FCF is 13.82 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
EV-to-FCF: 13.82 (61% above median its 10-year median of 8.61)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 30.3% below the Drug Manufacturers median (#197 of 566)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
